Dilip Solanki
Hematology & Oncology · Dallas, TXNPI 1124060116
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Eisai Inc. at 30.3% of the total. Reporting peaked in 2019 at $14,644 and has fallen 99.7% since, to $51 in 2025.
Across 108 payments — averaging $149.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$5K
- Kyowa Kirin, Inc.$5K
- Seagen Inc.$2K
- Merck$432
- Johnson & Johnson$429
- AstraZeneca$391
- plus $4K from 29 others
What the payments were for
- Consulting fees$7,46046%
- Speaking & faculty fees$1,5009%
- Travel & lodging$1,79811%
- Food & beverage$5,24032%
- Education$1981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 10 | $4,906 |
| Kyowa Kirin, Inc. | 12 | $4,839 |
| Seagen Inc. | 3 | $1,653 |
| Merck | 8 | $432 |
| Johnson & Johnson | 9 | $429 |
| AstraZeneca(2 entities) | 6 | $391 |
| AbbVie | 5 | $385 |
| Tesaro, Inc. | 4 | $264 |
| Astellas Pharma US Inc | 6 | $261 |
| Puma Biotechnology, Inc. | 2 | $240 |
| Regeneron Healthcare Solutions, Inc. | 2 | $234 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $195 |
| Rigel Pharmaceuticals, Inc. | 2 | $184 |
| Bayer | 3 | $165 |
| Pfizer | 4 | $150 |
| Sanofi | 3 | $149 |
| Array Biopharma Inc | 2 | $132 |
| Incyte Corporation | 2 | $131 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $129 |
| Gilead | 1 | $125 |
| Karyopharm Therapeutics Inc. | 1 | $121 |
| GSK | 1 | $111 |
| Heron Therapeutics, Inc. | 1 | $110 |
| Bristol Myers Squibb | 1 | $109 |
| Comsort, Inc | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 1 | $87 |
| Amgen | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Genentech USA, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
| Tersera Therapeutics LLC | 1 | $13 |
| Taiho Oncology, Inc. | 1 | $12 |
| EMD Serono, Inc. | 1 | $12 |
| Clovis Oncology, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,197 in reported general payments places this provider in the 75th percentile of 838 hematology & oncology providers in Texas.
Other hematology & oncology in Dallas
- Edward PearsonDallas$900K
- Christopher MaiselDallas$713K
- Ashwani AgarwalDallas$275K
- Katherine WangDallas$188K
- Houston HolmesDallas$178K
- Benjamin KitchensDallas$177K
- Farrukh AwanDallas$138K
- Dai Chu LuuDallas$90K
- Luis PineiroDallas$86K
- Joan SchillerDallas$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.